Latest News and Press Releases

1H 2023 Revenue Growth of 16% at CER to $180.8M Raising FY 2023 Galafold® Revenue Growth Guidance to 14%-18% at CER EU Launch of Pombiliti® + Opfolda® Underway; U.S. and U.K. Approvals Expected 3Q...

PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, August 8, 2023, at...

PHILADELPHIA, June 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for...

1Q23 Revenue Growth of 14% at CER to $86.3M On Track to Deliver Full-Year 2023 Galafold Revenue Growth of 12%-17% at CER U.S. FDA Pre-approval Inspection...

PHILADELPHIA, May 02, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2023 Health Care...

PHILADELPHIA, May 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 10, 2023, at...

        European Commission Approval of Opfolda and Commercial Launch of Pombiliti® + Opfolda® Anticipated in 3Q 2023 Upon Approval, Pombiliti + Opfolda will be the First Two-Component Therapy in the...

Approved as a Long-Term Enzyme Replacement Therapy in Combination with Miglustat for All Adults Living with Late-Onset Pompe Disease CHMP Opinion for Miglustat, the Oral Enzyme Stabilizer Component...

2022 Revenue Growth of 16% at CER to $329M Projecting Galafold Revenue Growth in 2023 of 12-17% at CER U.S. FDA Pre-approval Inspection for AT-GAA Now Scheduled; Approval expected in 3Q 2023 EU and...

PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference...